24 June, 2017
Its up 0.20, from 1.26 in 2016Q3. Buy rating has been given by 0 analysts to the company stock whereas 4 given UNDERPERFORM rating to stock and 3 given HOLD rating. 11 funds opened positions while 18 raised stakes. Hancock accumulated 13,010 shares. State Board Of Administration Of Florida Retirement holds 58,243 shares.
If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, SRNE earned gross profit of 1.78 Million, in 2015 2.64 Million gross profit, while in 2016 Sorrento Therapeutics, Inc. Gofen And Glossberg Ltd Il reported 10,000 shares.
Shares outstanding are recorded as 69.65 M and total shares floated are 42.12 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 0.60.
Relative Strength Index (RSI) for Sorrento Therapeutics, Inc.
EPS growth in past 5 year was -30.00% along with sales growth of 72.80% in the last five years. National Bank & Trust Of New York Mellon Corp reported 149,755 shares.
Headlines about Sorrento Therapeutics (NASDAQ:SRNE) have been trending somewhat negative on Wednesday, according to Accern.
Schneider Capital Management Corp increased Axcelis Technologies Inc stake by 62,458 shares to 391,563 valued at $5.70 million in 2016Q4. It was reported on Jun, 22 by Barchart.com. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. 40,000 shares were sold by Ng George K, worth $206,000 on Friday, February 3. The insider Herde Kevin bought $15,450. 425,277 shares of the company traded hands. Wu Yue Alexander had bought 5,000 shares worth $25,750. Sorrento Therapeutics has a 52-week low of $1.50 and a 52-week high of $8.35. They now have a United States dollars 11 price target on the stock. KCG Holdings Inc. bought a new stake in Sorrento Therapeutics during the first quarter worth approximately $108,000. Sorrento Therapeutics comprises 3.5% of Wildcat Capital Management LLC's investment portfolio, making the stock its 4th largest position. SRNE's total short interest was 3.27M shares in June as published by FINRA.
03/17/2015 - Sorrento Therapeutics, Inc. had its "outperform" rating reiterated by analysts at Zacks.
About 14,984 shares traded.
Sorrento Therapeutics, Inc. closed its last trading session at $2 with the loss of -12.5%. It has underperformed by 90.01% the S&P500. Sorrento Therapeutics, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0. The firm's market capitalization is $162.83 Million. The Firm is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. It now has negative earnings. The Company's primary therapeutic focus is oncology, including the treatment of chronic cancer pain.
HC Wainwright set a $20.00 target price on Sorrento Therapeutics, Inc. Therefore 100% are positive.
Several equities research analysts recently issued reports on SRNE shares. The firm has "Buy" rating by Brean Capital given on Wednesday, July 29. The rating was reinitiated by MLV with "Buy" on Monday, August 3. $17,904 worth of Sorrento Therapeutics Inc (NASDAQ:SRNE) was bought by SHAH JAISIM.
01/15/2014 - Sorrento Therapeutics, Inc. had its "buy" rating reiterated by analysts at Noble Financial. (Nasdaq: SBGI) ("Sinclair") in accordance with the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 8, 2017, pursuant to which Samson Merger Sub Inc., a wholly-owned subsidiary of Sinclair, will be merged with and into Tribune (the "Merger"), with Tribune surviving the merger as a wholly-owned subsidiary of Sinclair.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
